MusclePharm Corporation: Listing for Institutional Investment.
Brad Pyatt, Chief Executive officer of MusclePharm Corporation (OTCQB: MSLP) has informed some important developments of the company by issuing a news letter to the Shareholders on February 15, 2012. Brad Pyatt has once again confirmed that the company’s 850:1 reverse stock split was necessary to seek a listing on a stock exchange. Brad Pyatt pointed out, “we expect we will have such a listing this summer after we post our 2013 first quarter results. There are several benefits to being listed on a stock exchange, but the most important is the ability to seek institutional investment in our shares. The institutions that were looking at investing in our Company over the past few years declined for the most part, citing our lack of a stock exchange listing. Going forward, these investors will have the ability to participate in our Company once we are listed on an exchange”. From his speech, the CEO has given an implied hint that MusclePharm is going to post a good operating result in first quarter 2013. He says, “we project we will increase our gross revenues in 2013 to over $100 million”.
The management of each and every organization wants to increase the value their organization. An organization’s value depends on operating results; a good result brings good value and a poor result brings under value of the organization. Shareholders want to see that better performance and better return from organization. MusclePharm has been presenting operating losses to its shareholders, which has prevented the company from listing with main market. Shifting of a company from OTC market to main market increases enterprise value to a big extent. The CEO expects that with the successful listing of the company an opportunity of, institutional investment to the shares of MusclePharm will increase. As MusclePharm is a growing stage company, institutional investment is required to support its business expansion. However, a good profit margin is primary needs to shareholders of MusclePharm.